Asia-Pacific Journal of Ophthalmology最新文献

{"title":"A suspended anterior chamber nematode: Novel ivcm imaging of parasitic architecture","authors":"Xinhan Cui , Ning Lyu , Jun Xiang","doi":"10.1016/j.apjo.2025.100251","DOIUrl":"10.1016/j.apjo.2025.100251","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 1","pages":"Article 100251"},"PeriodicalIF":4.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145285532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Descemet membrane endothelial keratoplasty under failed sclerocorneal transplantation","authors":"Thibaud Garcin, Mathilde Kaspi, Nacim Bouheraoua, Vincent Borderie","doi":"10.1016/j.apjo.2025.100220","DOIUrl":"10.1016/j.apjo.2025.100220","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 1","pages":"Article 100220"},"PeriodicalIF":4.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A rare case of caruncular actinomycosis presenting with tumor-like features","authors":"Tatsuya Sakamoto, Kentaro Sueoka, Taiichiro Chikama","doi":"10.1016/j.apjo.2025.100202","DOIUrl":"10.1016/j.apjo.2025.100202","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 1","pages":"Article 100202"},"PeriodicalIF":4.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143967287","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intravitreal aflibercept 8 mg versus 2 mg in Asian patients with neovascular age-related macular degeneration: 48-week analysis of the Phase 3 PULSAR trial","authors":"Andrew Chang ,&nbsp;Xiaodong Sun ,&nbsp;Tomohiro Iida ,&nbsp;Timothy Y.Y. Lai ,&nbsp;Tien Y. Wong ,&nbsp;Chui Ming Gemmy Cheung ,&nbsp;Won Ki Lee ,&nbsp;Xin Zhang ,&nbsp;Andrea Schulze ,&nbsp;Ursula Maria Schmidt-Ott ,&nbsp;Min Zhao ,&nbsp;Zoran Hasanbasic ,&nbsp;Sergio Leal ,&nbsp;Shih-Jen Chen ,&nbsp;on behalf of the PULSAR study investigators","doi":"10.1016/j.apjo.2026.100278","DOIUrl":"10.1016/j.apjo.2026.100278","url":null,"abstract":"<div><h3>Purpose</h3><div>To evaluate 1-year efficacy and safety of aflibercept 8 mg in Asian patients with neovascular age-related macular degeneration (nAMD) in the PULSAR (NCT04423718) trial.</div></div><div><h3>Design</h3><div>Subgroup analysis of the Phase 3 PULSAR trial.</div></div><div><h3>Methods</h3><div>Patients aged ≥ 50 years with nAMD were randomized to receive intravitreal aflibercept 8 mg every 12 (8q12) or 16 (8q16) weeks, or aflibercept 2 mg every 8 weeks (2q8), following 3 initial monthly injections. Outcomes included change from baseline in best-corrected visual acuity (BCVA) and central subfield retinal thickness (CRT), durability, and safety at week (W) 48.</div></div><div><h3>Findings</h3><div>Overall, 234 Asian patients participated and received study treatment (8q12 [n = 74], 8q16 [n = 77], and 2q8 [n = 83]). At W48, the least squares (LS) mean (95 % CI) BCVA change from baseline was + 9.9 (6.9, 12.9), + 9.2 (7.1, 11.2), and + 7.6 (4.7, 10.5) letters in the 8q12, 8q16, and 2q8 groups, respectively. The LS mean (95 % CI) change in CRT from baseline to W48 for the 8q12, 8q16, and 2q8 groups was −141 (−152, −129), −156 (−167, −146), and −142 (−155, −129) µm, respectively. Most patients receiving 8q12 (85 %) or 8q16 (87 %), maintained their randomized dosing interval, through W48. The safety profile of aflibercept 8 mg was comparable to aflibercept 2 mg.</div></div><div><h3>Conclusions</h3><div>Aflibercept 8 mg was effective and well tolerated in Asian patients with nAMD, with demonstrated improvements in functional and anatomic outcomes comparable to aflibercept 2 mg at W48. Aflibercept 8 mg outcomes were achieved with fewer injections than with aflibercept 2 mg, consistent with overall PULSAR results.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 1","pages":"Article 100278"},"PeriodicalIF":4.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145948525","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Retinal toxicity after intracameral cefuroxime following cataract surgery","authors":"Xuejuan Cheng ,&nbsp;Lu Qiu ,&nbsp;Fei Cong ,&nbsp;Lei Gao","doi":"10.1016/j.apjo.2025.100206","DOIUrl":"10.1016/j.apjo.2025.100206","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"15 1","pages":"Article 100206"},"PeriodicalIF":4.5,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143963591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postoperative endophthalmitis rate associated with routine off-label reuse of single-use phacoemulsification cassettes in more than 1,000,000 consecutive surgeries","authors":"David F. Chang ,&nbsp;Aravind Haripriya","doi":"10.1016/j.apjo.2025.100247","DOIUrl":"10.1016/j.apjo.2025.100247","url":null,"abstract":"<div><div>According to a 2025 APAO survey, reuse of phacoemulsification tubing and cassettes appears to be more common in Asian-Pacific countries compared to Europe and North America. We analyzed the phacoemulsification postoperative endophthalmitis (POE) rate from 2016 to 2024 at the Aravind Eye Care System’s 15 hospital network. Single-use phacoemulsification cassettes were routinely reused all day (off label) at every facility during this 9-year period. The POE rate was 0.01 % in 1,133,959 consecutive cases. This rate was consistent from year to year and compared favorably with contemporaneous POE data from the American Academy of Ophthalmology Intelligent Research in Sight (IRIS) Registry (0.06 %), where presumably no reuse of phacoemulsification cassettes would have been allowed. We found no evidence that reusing the same phacoemulsification tubing and cassette all day increased the rate of POE.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"14 6","pages":"Article 100247"},"PeriodicalIF":4.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145190747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The whole life cycle myopia management","authors":"Moxin Chen ,&nbsp;Qin Shu ,&nbsp;Fang Li ,&nbsp;Lin Li ,&nbsp;Xianqun Fan","doi":"10.1016/j.apjo.2025.100161","DOIUrl":"10.1016/j.apjo.2025.100161","url":null,"abstract":"<div><div>Myopia stands as a prevalent ocular condition with global implications, impacting individuals at various life stages. In school-age children and adolescents, uncorrected myopia impedes reading and academic performance. Among middle-aged and elderly populations, myopia poses severe risks such as macular degeneration, macular holes and retinal detachment, leading to irreversible visual impairment. The term “myopia management” is widely embraced by ophthalmic practitioners and optometry associations worldwide, encompassing strategies to correct refractive errors and ongoing assessment of disease progression, aiming to reduce the progression of myopia and axial elongation. To date, current management strategies for myopia include public health policies, optical solutions, medical interventions and surgical options, but these interventions are general and lack age specificity. Despite existing interventions, we propose the concept of “Whole Life Cycle Myopia Management” in this review. This approach outlined major risk factors of myopia through the whole life cycle, discussed current interventions for myopia and provided age-specific management strategies for myopia of eight different life stages—infancies, toddlers, preschoolers, school-age children, adolescents, young adults, middle-age and old-age, including the prevention of myopia onset, slowing of myopia progression and monitoring of myopia complications. Achieving the “Whole Life Cycle Myopia Management” requires collaborations efforts from government, schools, hospitals and families, to restore vision and enhance the quality of life for those individuals affected by myopia.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"14 6","pages":"Article 100161"},"PeriodicalIF":4.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143057874","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Embracing the future: A new paradigm for addressing the global myopia epidemic","authors":"Hiu Ying Enne Leung,&nbsp;Lizhen Chen,&nbsp;Sun Li,&nbsp;Mingguang He","doi":"10.1016/j.apjo.2025.100264","DOIUrl":"10.1016/j.apjo.2025.100264","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"14 6","pages":"Article 100264"},"PeriodicalIF":4.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145530316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"International consensuses and guidelines on management of proliferative diabetic retinopathy (PDR) by the Asia-Pacific Vitreo-retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO) and the Academia Retina Internationalis (ARI)","authors":"Robert F. Lam ,&nbsp;Nishant V. Radke ,&nbsp;Francesco M. Bandello ,&nbsp;Pramod Bhende ,&nbsp;Yen-Ting Chen ,&nbsp;Gemmy C.M. Cheung ,&nbsp;Jay Chhablani ,&nbsp;Adrian T. Fung ,&nbsp;Yi-Ting Hsieh ,&nbsp;Chi-Chun Lai ,&nbsp;Vincent Y.W. Lee ,&nbsp;Xiaorong Li ,&nbsp;Tao Li ,&nbsp;Jennifer I. Lim ,&nbsp;William F. Mieler ,&nbsp;Onnisa Nanegrungsunk ,&nbsp;Dong Ho Park ,&nbsp;Tunde Peto ,&nbsp;Rajiv Raman ,&nbsp;Paisan Ruamviboonsuk ,&nbsp;Dennis S.C. Lam","doi":"10.1016/j.apjo.2025.100262","DOIUrl":"10.1016/j.apjo.2025.100262","url":null,"abstract":"<div><div>The management of proliferative diabetic retinopathy (PDR) presents both established consensus and ongoing controversies, particularly regarding emerging therapies (anti-vascular endothelial growth factor agents [VEGF], subthreshold laser and intravitreal steroids) versus conventional approaches (laser photocoagulation and vitrectomy). The Asia-Pacific Vitreo-retina Society (APVRS), the Academy of Asia-Pacific Professors of Ophthalmology (AAPPO) and the Academia Retina Internationalis (ARI) saw such a need to establish consensus and controversial statements on PDR management. They formed an international panel of experts (IPE) comprising 26 experts from 13 countries/territories to establish the statements, including diagnosis and diagnostic technologies, screening approaches, laser, anti-VEGF, intravitreal steroids and vitrectomy and related techniques in PDR management. The objective is to synthesize evidence-based real-world practice recommendations from leading global experts to guide the management of PDR. Of the 37 statements, the IPE reached consensus (75 % voted as “Strong Agreement” or “Agreement”) on 28 (76 %) statements. Controversial statements, such as panretinal photocoagulation (PRP) in special scenarios, use of steroids in cases unresponsive to anti-VEGF and PRP and during vitrectomy to improve visual oucomes, and specific surgical techniques such as internal limiting membrane peeling and drainage retinotomy in the treatment of PDR are identified. Given its high prevalence and propensity for visual morbidity, and the recent advances in surgery for PDR, confirming the standard practices and deliberating on controversies to find the best approach by international experts would help improve the management of PDR further.</div></div>","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"14 6","pages":"Article 100262"},"PeriodicalIF":4.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145480538","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Barriers to MIGS adoption among glaucoma specialists in India: Insights from a targeted survey","authors":"Sahebaan Sethi,&nbsp;Shweta Tripathi,&nbsp;Maneesh Singh,&nbsp;Nagalekshmi Ganesh,&nbsp;Mayav Movdawalla,&nbsp;Shahinur Tayab","doi":"10.1016/j.apjo.2025.100195","DOIUrl":"10.1016/j.apjo.2025.100195","url":null,"abstract":"","PeriodicalId":8594,"journal":{"name":"Asia-Pacific Journal of Ophthalmology","volume":"14 6","pages":"Article 100195"},"PeriodicalIF":4.5,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}